Suzanne Cory-Projects

Suzanne Cory-Projects


BH3 mimetic treatment of acute myeloid leukaemia

Using models of acute myeloid leukaemia (AML) induced by fusion oncoproteins that provoke human AML, we are analysing:

  1. Which BH3-only proteins are critical for the action of conventional AML therapeutics.
  2. Whether BH3 mimetics can be used in combination with these drugs to improve therapeutic outcomes.
  3. The impact of over-expression of anti-apoptotic proteins MCL-1 and BCL-2 on AML development and treatment.
Tumorigenic impact of loss of the MYC antagonist MNT

MYC and its family of related transcription factors are central to cell growth, proliferation, metabolism and apoptosis. Deregulated expression of MYC drives most human cancers.  

MNT antagonizes MYC by binding to MYC’s obligate DNA binding partner MAX. We have found that MYC-driven lymphomagenesis is slowed in a MNT+/- background, a phenotype consistent with increased susceptibility to apoptosis. We are now using conditional deletion to further reduce MNT levels and determine the impact on cell proliferation and apoptosis.